This is the second postcard in our mini-series on the emerging field of immunometabolism and the translational potential for cancer new product development.
Over the course of three weeks, we’ll be sharing six postcards from our journey, three of which are based around interviews with scientists at the forefront of research in this niche.
What did we learn about immunometabolism at AACR20?
In this latest post we’re taking a look at some of the signals at this year’s virtual AACR annual meeting, which as usual had a wealth of data on offer, offering as it does a window into the future of cancer drug development.
To learn more from our oncology analysis and get a heads up on insights and commentary on the emerging area of immunometabolism, subscribers can log-in or you can click to gain access to BSB Premium Content.
CAR T cell therapy for solid tumours is the cancer new product development equivalent of the quest for the “Holy Grail.” It remains one of the cell therapy challenges of the coming decade.
Light inspires and illuminates
In this post we shine the light on one of the world’s leading cell therapy experts who is taking on that challenge.
Most of our posts are what is known in the business as “long-form” and this one is no exception; it’s over 7,000 words long and offers a veritable smorgasbord of insights into new cell therapies for blood cancers and solid tumours, novel targets, as well as future directions, including a company in stealth mode…
Curious to learn more about this important topic on cracking the code and the quest to find solutions?
Then consider supporting independent science journalism by joining an exclusive group of readers around the world in academic medicine and industry who read BSB premium content.
To learn more from our oncology coverage and get a heads up on our latest analysis, commentary, plus an expert interview from a cellular therapy specialist in stealth mode, subscribers can log-in or you can click to gain access to BSB Premium Content.
Churchill College, Cambridge: Yesterday, the main focus at the EACR Cancer Genomics conference was on immunology-related topics as they pertain to genomics.
A rainy day in the Fens for #CG17
Unfortunately, however, the Great British summer ended as almost as soon as it started – I can confirm that it started on a Wednesday this year and fizzled out by the following Tuesday!
Consider that on the first two days of the conference it was gloriously sunny and those wooden benches were full of scientists sitting outside eagerly discussing their research or various collaborations afoot.
A mere 24 hours later, the heavens opened and steadfastly drizzled all day long, much to the chagrin of the attendees.
To learn more, subscribers can login or you can purchase access to BSB Premium Content.